Simcere Zaiming Inks ~$1.53B Licensing Deal with Roche for SIM0660

Shots: Simcere Zaiming has entered into an exclusive global licensing agreement with Roche for the development & commercialization of SIM0660, a potential treatment of B-cell-mediated diseases As per the deal, Roche will acquire exclusive global rights to develop, manufacture, & commercialize SIM0660 in exchange for ~$1.53B in total, incl. $75M in upfront, as well as…

ByRidhi RastogiSeptember 2, 2026

NEWS

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

Shots: Ipsen has entered into an exclusive licensing agreement with Simcere Zaiming for SIM0613 to treat solid tumors with the highest unmet needs Ipsen will secure global rights to SIM0613 outside Greater China, gain manufacturing rights after technology transfer, & assume responsibility for all development activities beyond Greater China, incl. P-I preparation & IND/CTA submissions As…

ByRidhi RastogiDecember 24, 2025

NEWS

NextCure Signs a ~$745M Licensing Agreement with Simcere Zaiming for SIM0505

Shots: Simcere has granted NextCure exclusive global rights to develop, manufacture, & commercialize SIM0505 to treat solid tumors, excl. Greater China, where Simcere will retain its rights As per the deal, Simcere will receive ~$745M in upfront, development, regulatory & sales milestones, along with net sales-based royalties up to double-digits outside of Greater China. NextCure…

ByRidhi RastogiJune 17, 2025

NEWS

AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma

Shots: AbbVie & Simcere Zaiming (subsidiary Simcere Pharma) have signed an option to license agreement for developing SIM0500, being assessed in P-I for r/r multiple myeloma (MM) in the US & China As per the terms, Simcere will get an upfront, up to $1.055B option fees & milestones plus net-sales-based tiered royalties outside Greater China…

ByRidhi RastogiJanuary 15, 2025

NEWS

The NMPA Approves Simcere Zaiming’s Enlituo (Biosimilar, Cetuximab Beta) as a 1L Treatment for Metastatic Colorectal Cancer (mCRC)

Shots: The NMPA has approved Enlituo + CT (FOLFIRI), a biosimilar version of cetuximab beta, as a 1L treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) The approval was based on a P-II/III trial (n=505) evaluating cetuximab beta + CT vs CT, showing a PFS of 13.133mos. vs 9.567mos., an ORR of 69.1% vs 42.3%…

ByDipanshu DixitJune 26, 2024

NEWS

Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management

Shots: Fermion & Simcere Pharma have entered into an exclusive license and collaboration agreement to develop FZ002-037 for pain management As per the agreement, Simcere secures exclusive rights to develop & commercialize FZ002-037 across Greater China (Mainland China, Hong Kong, Macau & Taiwan) in exchange for an undisclosed upfront, milestones and sales-based tiered royalties…

ByDipanshu DixitJanuary 20, 2025

NEWS

Ipsen Receives US FDA Breakthrough Therapy Designation for IPN60340 in Unfit Acute Myeloid Leukemia

Shots: The US FDA has granted Breakthrough Therapy Designation (BTD) to Ipsen’s investigational therapy IPN60340 (ICT01) in combination with venetoclax and azacitidine for the treatment of 1L unfit acute myeloid leukemia (AML) The designation was supported by data from the P-I/II (EVICTION) study (n=57), where IPN60340 + Ven-Aza showed encouraging response rates, including a near…

ByPrince GiriJanuary 14, 2026

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 16, 2025 – Jun 20, 2025)  

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, Animal Health & DigiHealth. Check out our full report below:   Johnson & Johnson Reports P-II (RedirecTT-1) Trial Data on Talvey + Tecvayli for R/R Multiple Myeloma Read More: J&J Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for…

ByRidhi RastogiJune 20, 2025

NEWS

Galderma to Present OLYMPIA Extension Study Data on Nemluvio for Prurigo Nodularis at ICD 2025

Shots: The OLYMPIA long-term extension study assessed Nemluvio in 508 pts with prurigo nodularis up to 4yrs., which were enrolled from the P-II or P-III (OLYMPIA 1 & 2) trials Interim analysis at Wk. 100 showed sustained improvement, with over 90% achieving ≥4-point itch reduction & 70% being itch-free or nearly itch-free per Peak-Pruritus Numerical…

ByRidhi RastogiJune 18, 2025

NEWS

Abbvie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Oncology and Immunology

Shots: AbbVie & Neomorph have partnered in a collaboration & option-to-license deal to develop molecular glue degraders for oncology & immunology, using Neomorph's molecular glue discovery As per the terms, Neomorph will receive upfront & is eligible for ~$1.64B in future option fee & milestones, plus net sales-based royalties Molecular glue degraders are…

BySenior EditorJanuary 24, 2025

Simcere Zaiming Inks ~$1.53B Licensing Deal with Roche for SIM0660

Ipsen Signs ~$1.06B Deal with Simcere Zaiming for SIM0613

NextCure Signs a ~$745M Licensing Agreement with Simcere Zaiming for SIM0505

AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma

The NMPA Approves Simcere Zaiming’s Enlituo (Biosimilar, Cetuximab Beta) as a 1L Treatment for Metastatic Colorectal Cancer (mCRC)

Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management

Ipsen Receives US FDA Breakthrough Therapy Designation for IPN60340 in Unfit Acute Myeloid Leukemia

PharmaShots Weekly Snapshots (Jun 16, 2025 – Jun 20, 2025)

Galderma to Present OLYMPIA Extension Study Data on Nemluvio for Prurigo Nodularis at ICD 2025

Abbvie Partners with Neomorph to Develop Novel Molecular Glue Degraders for Oncology and Immunology

Contact US

FOLLOW US